A novel mRNA cancer vaccine helps reduce the chances of melanoma patients’ tumors returning
A groundbreaking cancer vaccine, created for each patient based on their unique tumor, is showing promising results in reducing the risk of melanoma tumors reappearing after surgery. According to a major study released by drugmakers Moderna and Merck, the vaccine, called intismeran, reduced the likelihood of melanoma returning by 42% after two years compared to standard post-surgery treatment.
The personalized vaccine, made with Nobel Prize-winning mRNA technology, teaches the patient's immune system to recognize and attack "neoantigens" - protein markers that should not be present if the cancer re-emerges. While some investors reacted negatively to the full results, experts in the field see this as a significant step forward for cancer immunotherapy research, potentially applicable to various types of cancers.
Written by urgent.news from Winnipeg Free Press's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
